Topic
Galectin
About: Galectin is a research topic. Over the lifetime, 2076 publications have been published within this topic receiving 103409 citations. The topic is also known as: IPR001079 & Galectin.
Papers published on a yearly basis
Papers
More filters
Patent•
29 Oct 2018TL;DR: In this article, anti-Galectin-9 antibodies are used to diagnose and/or to treat diseases associated with Galectin 9, such as autoimmune diseases and solid tumors.
Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
2 citations
TL;DR: While galectin-3 shares many features with other galectins, including cellular compartmentalization and functions, it appears to be unique in its structural constituency in the N-terminal domain, which is rich in proline, glycine, and alanine.
Abstract: The galectin family is phylogenically conserved in metazoans,
presently consisting of 14 identified members in
mammals, and galectin-3 is one of the most abundant,
widely distributed, and well-stud
2 citations
Patent•
08 Nov 2016
TL;DR: In this article, a compound of the general formula was proposed for treating a disorder relating to the binding of a galectin to a ligand in a mammal, such as a human.
Abstract: The present invention relates to a compound of the general formula (1) wherein A is selected from a group of formula 2 B is selected from a group of formula 3 The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human
2 citations
TL;DR: In this paper, the roles of β-galactoside binding lectins in their antiviral functions against IAVs were reviewed. But only three lectins were reported to play a regulatory role in IAV infection.
Abstract: Animal lectins are proteins with carbohydrate recognition activity. Galectins, the β-galactoside binding lectins, are expressed in various cells and have been reported to regulate several immunological and physiological responses. Recently, some galectins have been reported to regulate some viral infections, including influenza A virus (IAV); however, the mechanism is still not fully understood. Thus, we aim to review systemically the roles of galectins in their antiviral functions against IAVs. The PRISMA guidelines were used to select the eligible articles. Results indicated that only Galectin-1, Galectin-3, and Galectin-9 were reported to play a regulatory role in IAV infection. These regulatory effects occur extracellularly, through their carbohydrate recognition domain (CRD) interacting with glycans expressed on the virus surface, as well as endogenously, in a cell-cell interaction manner. The inhibition effects induced by galectins on IAV infection were through blocking virus-host receptors interaction, activation of NLRP-3 inflammasome, augment expression of antiviral genes and related cytokines, as well as stimulation of Tim-3 related signaling to enhance virus-specific T cells and humoral immune response. Combined, this study concludes that currently, only three galectins have reported antiviral capabilities against IAV infection, thereby having the potential to be applied as an alternative anti-influenza therapeutic strategy.
2 citations
TL;DR: Results are likely to indicate that Gal-7 induction in epidermal keratinocytes causes both apoptotic cell death and HMGCS1-mediated cholesterol accumulation which will be phagocytized by macrophages, which may explain the pathogenesis of normolipemic cutaneous xanthoma.
2 citations